Roche, Biogen Idec, Inc. (Massachusetts) Report One Death In MS Drug Ocrelizumab Phase II Trial

October 18, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BOSTON, Oct 15 (Reuters) - Roche Holding AG (ROG.VX) and Biogen Idec Inc (BIIB.O) reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II

Biogen Roche